Global X Health & Wellness ETF (BFIT)
| Assets | $8.62M |
| Expense Ratio | 0.50% |
| PE Ratio | 17.27 |
| Shares Out | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -3.17% |
| Volume | 1,119 |
| Open | 21.51 |
| Previous Close | 21.39 |
| Day's Range | 21.39 - 21.51 |
| 52-Week Low | 19.92 |
| 52-Week High | 23.51 |
| Beta | n/a |
| Holdings | 1 |
| Inception Date | May 9, 2016 |
About BFIT
Fund Home PageThe Global X Health & Wellness ETF (BFIT) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund invests in companies whose revenue or main business purpose is encompassed by a cross- sector definition of health and wellness. Equities in this fund come from developed countries. BFIT was launched on May 9, 2016 and is issued by Global X.
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 28, 2023 | $0.25198 | Jan 8, 2024 |
| Jun 29, 2023 | $0.10129 | Jul 10, 2023 |
| Dec 29, 2022 | $0.11645 | Jan 9, 2023 |
| Jun 29, 2022 | $0.07839 | Jul 8, 2022 |
| Dec 30, 2021 | $0.14054 | Jan 7, 2022 |
| Jun 29, 2021 | $0.04131 | Jul 8, 2021 |
News
Global X ETFs To Liquidate 19 ETFs
NEW YORK , Jan. 19, 2024 /PRNewswire/ -- Global X ETFs, the New York-based provider of exchange-traded funds, today announced the scheduled liquidation of the following ETFs (the "Funds"), based on an...
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
U.S. Fund And ETF Investors Continue To Favor Foreign Issues In 2023
Investors were net purchasers of money market funds while being net redeemers of equity funds, tax-exempt fixed income funds, and taxable bond funds for the week. For the week, the average equity fund...
Finding 2040's FANMAG: Thematic ETFs For Long-Term Portfolios
FANMAG and FANMAG stocks are fine, but do these already-huge companies really have enough juice to give bona fide growth investors, especially younger investors, what they really need.